This content is from: United States

GSK fights $5.2 billion IRS claim

GlaxoSmithKline (GSK), the UK-based pharmaceutical company, has received a demand for $5.2 billion in additional taxes and interest from the US Internal Revenue Service (IRS) over its transfer pricing calculations for legacy company Glaxo Wellcome from 1989 to 1996

January 31 2005

To access our market-driven intelligence please request a trial here.

Read this article – and more – for a 30 day period.

REQUEST ACCESS

Are you already an ITR subscriber? Log in here

Instant access to all of our content. Membership Options | 30 Day Trial

This content is from: Direct Tax

Glaxo challenges $2.7 billion transfer pricing claim
April 10 2004
This content is from: Direct Tax

Glaxo challenges $2.7 billion transfer pricing claim
April 17 2004
This content is from: Direct Tax

GSK fights $5.2 billion in back taxes
January 11 2004
This content is from: Sponsored

Authorities challenge GlaxoSmithKline's tax positions
February 12 2008

GSK fights $5.2 billion IRS claim

Editorial

Subscriptions

Business Development

Customer Services

Related